Drug Use Review (DUR) Board Drug Use Review (DUR) Board Formulary Committee DUR Board Meeting Agendas Some documents on this page are legal and/or historical in nature and cannot be altered to meet 508 Accessibility standards. Each of those documents has a corresponding .txt document with the same name placed next to it. 2017 Agendas December 6, 2017 rev. 1130/2017 September 27, 2017 April 26, 2017 - PDL Revised 04/07/2017 - DOI Link, Feldman Int J Chron Obstruct Pulmon Dis - Epclusa® Clinical Review Summary - Taltz® Medical Value Summary - EucrisaTM AMCP Dossier - Med Info Letter Xeljanz® XR Text Version: Med Info Letter Xeljanz® XR - Montana Medicaid Final Chantix® March 29, 2017 - PDL Revised 03/14/2017 - Rexulti® - Restasis® - Aristada® February 15, 2017 - PDL - Chest Guidelines for VTE Servlet - Entresto® Text Version: Entresto® - Ocaliva® Letter - Ocaliva® AMCP Dossier - Summary Eliquis® Servlet January 25, 2017 - DURB 2016 Agendas September 28, 2016 August 31, 2016 Revised 08.18.2016 April 27, 2016 Revised 04.21.2016 - Dyanavel XR® Formulary Submission Text Version: Dyanavel XR® Formulary Submission - Pfizer Medical Information for QuilliChew ER C-II Text Version: Pfizer Medical Information for QuilliChew ER C-II - A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of SchizophreniaJ Clin Psychiatry Meltzer et al. 2015 Text Version: A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil March 30, 2016 Revised 03.09.2016 - Cosentyx ® (secukinumab) Clinic Summary Text Version: Cosentyx ® (secukinumab) Clinic Summary - Humira® (Adalimumab) Medicaid Testimony Text Version: Humira® (Adalimumab) Medicaid Testimony - Seebri® Neohaler® (glycopyrrolate) inhalation powder Clinical Summary Text Version: Seebri® Neohaler® (glycopyrrolate) inhalation powder - Technivie® (ombitasvir, paritaprevir, and ritonavir tablets) Medicaid Testimony Text Version: Technivie® (ombitasvir, paritaprevir, and ritonavir tablets) - Tudorza ® Pressair® (Aclidinium bromide inhalation powder) Clinical Executive Summary Text Version: Tudorza ® Pressair® (Aclidinium bromide inhalation powder) - Utibron ® Neohaler® (indacaterol and glycopyrrolate) inhalation powder Clinical Summary Text Version: Utibron ® Neohaler® (indacaterol and glycopyrrolate) February 17, 2016 - Initial Use of Ambrisentan Plus Tadalafil in Pulmonary Arterial Hypertension for AMBITION investigators N Engl J Med 373;9 nejm.org August 27, 2015 Text Version: Initial Use of Ambrisentan Plus Tadalafil in Pulmonary Arterial Hypertension - Supplementary Appendix to Initial Use of Ambrisentan Plus Tadalafil in Pulmonary Arterial Hypertension N Engl J Med 2015;373:834-44. DOI: 10.1056/NEJMoa1413687 Text Version: Supplementary Appendix to Initial Use of Ambrisentan Plus Tadalafil - Entresto® (sacubitril and valsartan) Clinical Summary for Formulary Review Text Version: Entresto® (sacubitril and valsartan) - Montana Medicaid Repatha (Evolucumab) Submission Text Version: Montana Medicaid Repatha (Evolucumab) Submission - Movantik Text Version: Movantik January 20, 2016 2015 Agendas October 28, 2015 September 30, 2015 Rev. 09.16.2015 April 29, 2015 - Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity:results from a randomized controlled trial in relapsing-remitting multiple sclerosis Arnold et al. BMC Neurology Text Version: Effect of peginterferon beta-1a - Bunavail® (Buprenorphine/naloxone) Text Version: Bunavail® (Buprenorphine/naloxone) - Hysingla® Formulary Dossier Text Version: Hysingla® Formulary Dossier - Lemtrada™ Text Version: Lemtrada™ - Abilify® (aripiprazole) Testimony – Montana Medicaid Text Version: Abilify® (aripiprazole) - Plegridy™ Summary Medicaid Pharmacy &Therapeutics Committee Text Version: Plegridy™ Summary - Suboxone® Sublingual Film Text Version: Suboxone® Sublingual Film - Novel Buccal Film Formulation of Bupenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence:A 12-Week Conversion Study Sullivan and Webster, Clinical Therapeutics/2015 Text Version: Novel Buccal Film Formulation of Bupenorphine-Naloxone - Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures Fountain, et al. Epilepsia, 54(1):58–65, 2013 Text Version: Safety and tolerability of adjunctive lacosamide intravenous loading dose March 25, 2015 Revised 03.04.2015 - Arnuity Product Summary - Incruse Ellipta Prescribing Information - Incruse Ellipta Product Summary - Otezla Medicaid Summary - Ruconest Dossier February 18, 2015 Revised 02.10.2015 - Akynzeo® Formulary Dossier - Trulicity™ Medical Value Summary, November 3, 2014 - Tanzeum™ Product Summary - Viekira Pak® Medicaid Clinical Summary, December 2014 - Xigduo™ XR Clinical Summary, November 2014 January 28, 2015 DUR Board Meeting Minutes 2017 Minutes September 27, 2017 April 26, 2017 March 17, 2017 Revised 04/19/2017 February 15, 2017 January 25, 2017 2016 Minutes September 28, 2016 August 31, 2016 April 27, 2016 revised 05.16.2016 March 30, 2016 February 17, 2016 January 20, 2016 2015 Minutes October 28, 2015 September 30, 2015 April 29, 2015 March 25, 2015 February 18, 2015 January 28, 2015 Revised 02.27.2015 2014 Minutes October 15, 2014 September 17, 2014 April 23, 2014 March 26, 2014 February 19, 2014 January 29, 2014 To locate older documents, access the Archive Page.